60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris 60 Degrees Pharmaceuticals will Sponsor Pre-Clinical Studies ofTafenoquine Use in Candida spp, Including Candida auris

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...

Hardy Diagnostics Releases HardyCHROM™ Candida + auris SANTA MARIA, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Hardy Diagnostics is pleased to announce its release of HardyCHROM™ Candida + auris, a chromogenic media recommended for the selective...

Ondine Biomedical Inc. to Present Candida auris Program Results at the 5th International Conference on Prevention & Infection Control (ICPIC, 2019, Geneva) Vancouver, Canada, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Ondine Biomedical Inc. announces presentation of data demonstrating high levels of efficacy of its Photodisinfection program against Candida...

PositiveID to Exhibit its Caregiver Non-Contact Thermometer at the American Association of Critical-Care Nurses Exposition May 22-24 DELRAY BEACH, Fla., May 21, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that...